Viracta Therapeutics

84 articles with Viracta Therapeutics

• Viracta Therapeutics Announces New Employment Inducement Grant - May 13, 2022

  5/13/2022

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 110,000 shares of common stock.

• Viracta Therapeutics to Present at Upcoming May 2022 Investor Conferences

  5/11/2022

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management will present and participate in one-on-one meetings at the following investor conferences in May.

• Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

  5/10/2022

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the first quarter of 2022 and provided an update on recent corporate progress.

• Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

  4/20/2022

  Viracta Therapeutics, Inc. will host a key opinion leader (KOL) webinar on Nana-val (nanatinostat and valganciclovir) for the treatment of advanced Epstein-Barr virus-positive (EBV+) solid tumors on Wednesday, April 27, 2022, at 11:00 AM EDT.

• Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/7/2022

  Viracta Therapeutics, Inc. announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT.

• Viracta Therapeutics Announces New Employment Inducement Grant

  3/18/2022

  Viracta  Therapeutics, Inc. today announced that the Compensation Committee of Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase an aggregate of 200,000 shares of common stock.

• Viracta Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

  3/16/2022

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the fourth quarter and full year 2021 and provided an update on recent corporate activities.

• Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

  3/9/2022

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference.

• Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

  1/31/2022

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been dosed in the multinational Phase 1b/2 trial of its all-oral combination product, Nana-val.

• Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

  1/4/2022

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.

• Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

  12/16/2021

  Viracta Therapeutics, Inc. today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

• Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

  12/13/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced that final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma (VT3996-201) were presented in an oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting by Bradley Haverkos, M.D., Associate Professor at the University of Colorado School of Medicine.

• Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021

  12/13/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced the presentation of new preclinical data on vecabrutinib, a reversible inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK), in oral and poster presentations at the 2021 American Society of Hematology (ASH) Annual Meeting.

• Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma

  11/29/2021

  Viracta Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted its all-oral combination product candidate, nanatinostat and valganciclovir (Nana-val), orphan drug designation (ODD) for the treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS).

• Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/10/2021

  Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the third quarter of 2021 and provided an update on recent corporate activities.

• Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance

  11/5/2021

  Viracta Therapeutics, Inc. today announced that the Company has entered into a loan and security agreement with Silicon Valley Bank (SVB) and Oxford Finance LLC (Oxford) for up to $50.0 million

• Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting

  11/4/2021

  Viracta Therapeutics, Inc. today announced the acceptance of two abstracts for oral presentation and one for a poster presentation at the upcoming 2021 American Society of Hematology (ASH) Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia and virtually.

• Viracta Therapeutics to Present at Upcoming Investor Conferences - Nov 01, 2021

  11/1/2021

  Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences.

• Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

  10/6/2021

  Viracta Therapeutics, Inc. today announced the initiation of a multinational Phase 1b /2 trial in patients with EBV + solid tumors.

• Viracta Therapeutics to Present at Upcoming Investor Conferences in September

  9/7/2021

  Viracta  Therapeutics, Inc. today   announced that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021